Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
activated platelet-rich plasma + autologous fat transfer
- Development stage
- Unknown
- Lead developer
- Bergman Clinics
- Modality
- Cell Therapies
- Administration
- Subcutaneous, Intramuscular
01
Overview
This investigational combination therapy involves the addition of activated Platelet Rich Plasma (aPRP) to autologous fat transfer (lipofilling) for the treatment of facial volume loss, specifically in the midface region. Developed by Bergman Clinics in collaboration with the University Medical Centre Groningen, the treatment utilizes the patient's own blood, which is processed via a centrifuge system (GPS System) and activated with calcium to release a high concentration of growth factors. The biological rationale is that these growth factors, such as PDGF, TGF-beta, and VEGF, enhance the survival of the fat graft and promote skin rejuvenation by stimulating angiogenesis and modulating adipose-derived stem cells. Clinical trial results indicated that while the addition of PRP significantly reduced postoperative recovery time, it did not show a statistically significant improvement in long-term graft volume maintenance or skin elasticity compared to fat transfer alone.
- Other names
- PRP-enriched lipofillingactivated Platelet Rich Plasma in Human Autologous Fat TransferaPRP + lipofilling
Beyond the preview
Go deeper on activated platelet-rich plasma + autologous fat transfer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on activated platelet-rich plasma + autologous fat transfer.